REGENXBIO INC (RGNX:NASDAQ)
$7.2 -0.21 (-2.834%)
Analysed REGENXBIO INC (RGNX:NASDAQ) News Sources
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
25-08-2026
yahoo.com
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
05-09-2026
yahoo.com
REGENXBIO to Participate in Upcoming Investor Conferences
08-09-2026
yahoo.com
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
24-09-2026
yahoo.com
Regenxbio stock gains on positive gene therapy trial data
25-09-2026
yahoo.com
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
05-10-2026
stocktwits.com
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
12-10-2026
yahoo.com
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
21-10-2026
marketbeat.com
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
29-10-2026
yahoo.com
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
29-10-2026
yahoo.com
What is the current price of REGENXBIO INC (RGNX:NASDAQ)?
The current price of REGENXBIO INC (RGNX:NASDAQ) is $7.2.
REGENXBIO INC (RGNX:NASDAQ) absolute price change since previous trading day?
The absolute price change of REGENXBIO INC (RGNX:NASDAQ) since the previous trading day is $-0.21.
REGENXBIO INC (RGNX:NASDAQ) percentage price change since previous trading day?
The percentage price change of REGENXBIO INC (RGNX:NASDAQ) since the previous trading day is -2.834%.
What is the most recent average sentiment score for REGENXBIO INC (RGNX:NASDAQ)?
The most recent average sentiment score for REGENXBIO INC (RGNX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for REGENXBIO INC (RGNX:NASDAQ)?
The most recent sentiment for REGENXBIO INC (RGNX:NASDAQ) is .
SEC-8K** Filing Available For REGENXBIO INC (RGNX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.